Human GAD Autoantibody ELISA Kit

(Cat. No.: 31840)

• Glutamic acid decarboxylase autoantibodies (GADA) are found in 70% to 80% of individuals with new- onset type 1 diabetes, making it the most frequent autoantibody in autoimmune diabetes. GADA can be detected in serum for many years post diagnosis, and high concentrations of GADA have been considered as a marker of faster beta-cell exhaustion in these patients. Furthermore, GADA in non- diabetic individuals predicts the later development of type 1 diabetes1. Besides autoimmune diabetes, GADA also exists in Stiff Man Syndrome, autoimmune poly- endocrinopathies, and some of Grave’s Disease patients2.

• This cut off has been validated at ImmunoDiagnostics. However, we recommend each laboratory establish its own reference ranges of GADA levels to distinguish healthy and pathological subjects, as well as include its own internal control samples in the assay.
  ImmunoDiagnostics has generated a series of insect cell-derived bioactive recombinant proteins, along with a highly sensitive and specific ELISA kit for precision detection of GAD autoantibody (GADA) titers in human serum (Plasma samples are not recommended).
• Kit size: 96 tests

References:

1. Liu B, et al. Past, present and future of latent autoimmune diabetes in adults. Diabetes Metab Res Rev. 2019 Jul 18:e3205.
2. Björk E, et al. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes. Diabetes. 1994 Jan;43(1):161- 5.